Cartesian Operating Margin from 2010 to 2026
| RNAC Stock | 6.47 0.03 0.46% |
Check Cartesian Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cartesian Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.4 M, Interest Expense of 0.0 or Selling General Administrative of 21.7 M, as well as many indicators such as Price To Sales Ratio of 13.03, Dividend Yield of 0.0 or Days Sales Outstanding of 8.94. Cartesian financial statements analysis is a perfect complement when working with Cartesian Therapeutics Valuation or Volatility modules.
Cartesian | Operating Margin | Build AI portfolio with Cartesian Stock |
Analyzing Cartesian Therapeutics's Operating Margin over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Operating Margin has evolved provides context for assessing Cartesian Therapeutics's current valuation and future prospects.
Latest Cartesian Therapeutics' Operating Margin Growth Pattern
Below is the plot of the Operating Profit Margin of Cartesian Therapeutics over the last few years. It is Cartesian Therapeutics' Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cartesian Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (46.61) % | 10 Years Trend |
|
Operating Profit Margin |
| Timeline |
Cartesian Operating Margin Regression Statistics
| Arithmetic Mean | (25.39) | |
| Geometric Mean | 3.39 | |
| Coefficient Of Variation | (294.39) | |
| Mean Deviation | 38.75 | |
| Median | (4.29) | |
| Standard Deviation | 74.76 | |
| Sample Variance | 5,589 | |
| Range | 308 | |
| R-Value | 0.07 | |
| Mean Square Error | 5,932 | |
| R-Squared | 0.01 | |
| Significance | 0.79 | |
| Slope | 1.05 | |
| Total Sum of Squares | 89,421 |
Cartesian Operating Margin History
About Cartesian Therapeutics Financial Statements
Cartesian Therapeutics stakeholders use historical fundamental indicators, such as Cartesian Therapeutics' Operating Margin, to determine how well the company is positioned to perform in the future. Although Cartesian Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Cartesian Therapeutics' assets and liabilities are reflected in the revenues and expenses on Cartesian Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Cartesian Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Cartesian Therapeutics is entity of United States. It is traded as Stock on NASDAQ exchange.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Cartesian Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cartesian Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cartesian Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cartesian Therapeutics Stock:Check out the analysis of Cartesian Therapeutics Correlation against competitors. For information on how to trade Cartesian Stock refer to our How to Trade Cartesian Stock guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Will Biotechnology sector continue expanding? Could Cartesian diversify its offerings? Factors like these will boost the valuation of Cartesian Therapeutics. Anticipated expansion of Cartesian directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Cartesian Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth (0.07) | Earnings Share (1.33) | Revenue Per Share | Quarterly Revenue Growth 0.168 | Return On Assets |
The market value of Cartesian Therapeutics is measured differently than its book value, which is the value of Cartesian that is recorded on the company's balance sheet. Investors also form their own opinion of Cartesian Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cartesian Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Cartesian Therapeutics' market value can be influenced by many factors that don't directly affect Cartesian Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Cartesian Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cartesian Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Cartesian Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.